Telomerase in urological malignancy

Journal of Urology

Volumn 166, Issue 2, 2001, Pages 666-673

  Orlando, Claudio ^a   Gelmini, Stefania ^b   Selli, Cesare ^b   Pazzagli, Mario ^b  

^a UNIVERSITY OF FLORENCE   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Bladder; Kidney; Prostate; Telomerase; Testis

Indexed keywords

TELOMERASE;

BLADDER CARCINOMA; CANCER THERAPY; DIAGNOSTIC VALUE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME INHIBITION; HUMAN; KIDNEY CARCINOMA; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REVIEW; TREATMENT PLANNING;

EID: 0034942885     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)66040-5     Document Type: Review

References (159)

1. Replicative senescence: Implications for in vivo aging and tumor suppression
2. The limited in vitro lifetime of human diploid cell strains
3. Telomeres, telomerase, and myc. An update
4. The emerging p53 gene family
5. Regulation of the p53 protein by the MDM2 oncoprotein. 38th G. H. A. Clowes Memorial Award Lecture
6. Role of the retinoblastoma protein family, pRB, p107, and p130 in the negative control of cell growth
7. Telomeres, telomerase and immortality
8. Structure and function of telomeres
9. Telomeres, telomerase and cancer: Is the magic bullet real?
10. Applications of telomerase research in the fight against cancer
11. Human telomeres are attached to the nuclear matrix
12. The telomere and telomerase: Nucleic acid-protein complexes acting in a telomere homeostasis system. A review
13. Life and cancer without telomerase
14. A critical role for telomeres in suppressing and facilitating carcinogenesis
15. Role of telomerase in cellular proliferation and cancer
16. Multiple pathways for the regulation of telomerase activity
17. Cellular senescence and cancer
18. Telomeres and telomerase: Biological and clinical importance
19. Mammalian telomeres and telomerase
20. The telomere and telomerase: How do they interact?
21. Telomeres and telomerase
22. Bladerunners and telomerases
23. Telomeres, telomerase and cancer
24. Role of telomerase in normal and cancer cells
25. Telomeres, telomerase and cancer: An up-date
26. Telomerase activity in human germline and embryonic tissues and cells
27. Telomerase activity in normal and malignant hematopoietic cells
28. Telomerase activity in normal leukocytes and in hematologic malignancies
29. Telomerase activity in human intestine
30. Telomerase activity in the regenerative basal layer of the epidermidis in human skin and in immortal and carcinoma-derived skin keratinocytes
31. Telomerase activity in normal human epithelial cells
32. Telomerase activity in human endometrium
33. Telomerase activity concentrates in the mitotically active segments of human hair follicles
34. Telomerase activity in normal and neoplastic breast
35. Reconstitution of telomerase activity in normal human cells leads to elongation of telomeres and extended replicative life span
36. Specific association of telomerase activity with immortal cells and cancer
37. Telomerase activity in human breast tumors
38. Telomerase activity in benign and malignant thyroid tumors
39. Application of telomerase assay for the screening of cervical lesions
40. Telomerase activity: A marker to distinguish follicular thyroid adenoma from carcinoma
41. Detecting human bladder carcinoma cells in voided urine samples by assaying for the presence of telomerase activity
42. Correlating telomerase activity levels with human neuroblastoma outcomes
43. Telomerase activity in gastric cancer
44. Telomerase in the early detection of cancer
45. Telomerase activity in human cancer
46. Advances in quantification and characterization of telomerase activity by the telomeric repeat amplification protocol (TRAP)
47. Telomerase activity in lung cancer cells obtained from bronchial washings
48. A rapid, useful and quantitative method to measure telomerase activity by hybridization protection assay connected with a telomeric repeat amplification protocol
49. Enhanced detection of human telomerase activity
50. Rapid, quantitative nonisotopic assay for telomerase activity in human tumors
51. Telomerase activity is significantly enhanced in malignant adrenocortical tumors in comparison to benign adrenocortical adenomas
52. Comparison of telomerase activity in bladder carcinoma and exfoliated cells collected in urine and bladder washings, using a quantitative assay
53. Real-time quantification of human telomerase reverse transcriptase mRNA in tumors and healthy tissues
54. Telomerase activity in human development is regulated by human telomerase reverse transcriptase (hTERT) transcription and by alternative splicing of hTERT transcripts
55. Telomerase activity in human renal cell carcinoma
56. Telomerase activity and telomere lengths: Alterations in renal cell carcinomas
57. Determination of telomerase activity for differential analysis of multifocal renal cell carcinomas
58. Determination of telomerase activity in multifocal renal cell carcinoma
59. Telomerase activity in human renal cell carcinoma
60. Telomerase activity in malignant and benign renal tumors
61. hTERT is a critical determinant of telomerase activity in renal-cell carcinoma
62. Telomerase activity in renal cell carcinoma
63. Loss of heterozygosity at chromosome 3p correlates with telomerase activity in renal cell carcinoma
64. Genetic changes and telomerase activity in human renal cell carcinoma
65. Low frequency of positive telomerase activity in a chromophobe subtype of renal cell carcinoma
66. Telomerase activity in human renal cell carcinoma
67. Restoration of the cellular senescence program and repression of telomerase by human chromosome 3
68. The clinical implications of telomerase activity in upper tract urothelial cancer and washings
69. High telomerase reverse transcriptase (hTERT) messenger RNA level correlates with tumor recurrence in patients with favorable histology Wilms' tumor
70. Urinary markers of malignancy
71. Bladder cancer
72. Ancillary methods for the detection of recurrent urothelial neoplasia
73. Telomerase in human bladder cancer
74. Urine cytology. It is still the gold standard for screening?
75. Telomerase activity as a potential marker in preneoplastic bladder lesions
76. Bladder cancer
77. Urinary telomerase and its possible role as a marker for bladder cancer
78. Applications of telomerase in urologic oncology
79. Use of urine-based markers for detection and monitoring of bladder cancer
80. Telomerase activity in urine after transurethral resection of superficial bladder cancer and early recurrence
81. Limitations of urinary telomerase activity measurement in urothelial cancer
82. Subsequential telomerase activity in exfoliated urinary cells detects recurrent disease in bladder cancer after transurethral resection
83. Telomerase activity in patients with transitional cell carcinoma: A preliminary study
84. Comparison of screening methods in the detection of bladder cancer
85. A combination of semi-quantitative telomerase assay and in-cell telomerase activity measurement using exfoliated urothelial cells for the detection of urothelial neoplasia
86. Telomerase activity in malignant and benign bladder conditions
87. Semi-quantitative analysis of telomerase activity in exfoliated human urothelial cells and bladder transitional cell carcinoma
88. Expression of human telomerase subunits and correlation with telomerase activity in urothelial cancer
89. Evaluation of the telomeric repeat amplification protocol (TRAP) assay for telomerase as a diagnostic modality in recurrent bladder cancer
90. Sensitivity and specificity of NMP-22, telomerase, and BTA in the detection of human bladder cancer
91. Comparison of human telomerase RNA and telomerase activity in urine for diagnosis of bladder cancer
92. Non-radioactive measurement of telomerase activity in human bladder cancer, bladder washings, and in urine
93. Telomerase: A potential marker of bladder transitional cell carcinoma in bladder washes
94. Microsatellite analysis and telomerase activity in archived tissue and urine samples of bladder cancer patients
95. Telomerase activity in bladder carcinoma and its implication for noninvasive diagnosis by detection of exfoliated cancer cells in urine
96. Detection of telomerase activity in exfoliated cells in urine from patients with bladder cancer
97. Telomerase activity in human urothelial tumors
98. Telomerase activity in human bladder cancer
99. Quantitative measurement of telomerase reverse transcriptase (hTERT) mRNA in urothelial cell carcinomas
100. Evidence for elevated telomerase activity in small cell carcinoma of the bladder
101. Expression of the catalytic subunit associated with telomerase gene in human urinary bladder cancer
102. Expression of telomerase mRNA component (hTR) in transitional cells carcinoma of the upper urinary tract
103. Detection of human telomerase reverse transcriptase messenger RNA in voided urine samples as a useful diagnostic tool for bladder cancer
104. Limitations on the quantitative determination of telomerase activity by the electrophoretic and ELISA based TRAP assays
105. Telomerase activity: A prevalent marker of malignant human prostate tissue
106. Effects of androgens on telomerase activity in normal and malignant prostate cells in vitro
107. Telomerase activity in needle biopsies from prostate cancer and benign prostates
108. Focal intratumoral heterogeneity for telomerase activity in human prostate cancer
109. Relative contribution of normal and neoplastic cells determines telomerase activity and telomere length in primary cancers of the prostate, colon, and sarcoma
110. Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN)
111. Detection of telomerase activity in prostate needle-biopsy samples
112. Telomerase activity in prostate cancer, prostatic intraepithelial neoplasia, and benign prostatic epithelium
113. Detection of telomerase activity in prostate cancer by needle biopsy
114. Telomerase activity in human benign prostate tissue and prostatic adeno-carcinomas
115. Detection of telomerase activity in human prostate: A diagnostic marker for prostatic cancer?
116. Telomerase activity in primary prostate cancer
117. Telomerase activity in needle biopsies from prostate cancer and benign prostates: The influence of sampling bias
118. Expression of the RNA component of human telomerase (hTR) in prostate cancer, prostatic intraepithelial neoplasia, and normal prostate tissue
119. Htert expression correlates with MYC over-expression in human prostate cancer
120. Myc activates telomerase
121. Essential role of mouse telomerase in highly proliferative organs
122. Telomerase activity in germ cell cancers and mature teratomas
123. Inhibition of telomerase activity by cisplatin in human testicular cancer cells
124. Toward identifying a cellular determinant of telomerase repression
125. Novel anticancer drug discovery
126. Telomerase as an anti-cancer drug target: Will it fulfill its early promise?
127. Telomerase as an anti-cancer target: Current status and future prospects
128. Telomerase as a possible target for anticancer therapy
129. Telomerase. A target for anticancer therapy
130. Telomerase: The search for a universal cancer vaccine
131. Telomerase: A therapeutic target for the third millennium?
132. Target therapy of human malignant glioma in a mouse model by 2-5A antisense directed against telomerase RNA
133. The RNA component of human telomerase
134. Antisense telomerase treatment: Induction of two distinct pathways, apoptosis and differentiation
135. Telomerase inhibition by induced expression of antisense RNA
136. Inhibition of human telomerase by a retrovirus expressing telomeric anti-sense RNA
137. Inhibition of human telomerase activity by peptide nucleic acids
138. Cellular delivery of peptide nucleic acids and inhibition of human telomerase
139. Identifications of determinants of inhibitor binding within the RNA active site of human telomerase using PNA scanning
140. The 5′-end of hTERT mRNA is a good target for hammerhead ribozyme to suppress telomerase activity
141. Hammerhead ribozyme-mediated inhibition of telomerase activity in extracts of human hepatocellular carcinoma cells
142. Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells
143. Synthetic 2′-O-methylmodified hammerhead ribozymes targeted to the RNA component of telomerase as sequence-specific inhibitors of telomerase activity
144. Effects of reverse transcriptase inhibitors of telomere length and telomerase activity in two immortalized human cell lines
145. Irreversible telomere shortening by 3′-azido-2′,3′-dideoxythymidine (AZT) treatment
146. Human telomerase inhibition by 7-deaza-2′-deoxypurine nucleoside triphosphates
147. Telomerase from human leukemia cells: Properties and its interaction with deoxynucleoside analogues
148. Reverse transcriptase inhibitors suppress telomerase function and induce senescence-like processes in cultured mouse fibroblasts
149. Detection of telomerase in Chinese hamster V79 cells and inhibition by 7-deaza-deoxy guanosine triphosphate and (TTAGGG)4 in vitro
150. G-Quadruplex DNA as a target for drug design
151. G-Quadruplexes as a targets for drug design
152. Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells
153. Cationic porphyrins as telomerase inhibitors: The interaction of tera-(N-methyl-4-pyridyl)porphin with quadruplex DNA
154. Inhibition of human telomerase by a G-quadruplex-interactive compound
155. 1,4-And 2,6-disubstituted amidoanthracene-9, 10-dione derivatives as inhibitors of human telomerase
156. NMR-based model of telomerase-inhibiting compound bound G-quadruplex DNA
157. Tankyrase, a poly(ADPribose) polymerase at human telomeres
158. Telomerase activity in normal and malignant mammalian tissues: Feasibility of telomerase as a target for cancer chemotherapy
159. Inhibition of telomerase increases the susceptibility of human malignant glioblastoma cells to cisplatin-induced apoptosis